Repurposed Drugs to Enhance the Therapeutic Potential of Oligodendrocyte Precursor Cells Derived from Adult Rat Adipose Tissue
Failure in the proliferation, recruitment, mobilization, and/or differentiation of oligodendrocyte precursor cells (OPCs) impedes remyelination in central nervous system (CNS) demyelinating diseases. Our group has recently achieved the generation of functional oligodendroglia through direct lineage conversion by expressing <i>Sox10</i>, <i>Olig2</i>, and <i>Zfp536</i> genes in adult rat adipose tissue-derived stromal cells. The present study aimed to determine whether various repurposed drugs or molecules could enhance the myelinating capacities of these induced OPCs (iOPCs). We report that kainate, benztropine, miconazole, clobetasol, and baclofen promote in vitro iOPCs migration, differentiation, and ensheathing abilities through mechanisms similar to those observed in rat neural stem cell-derived OPCs. This research supports the potential use of iOPCs as they provide an alternative and reliable cell source for testing the effects of in vitro promyelinating repurposed drugs and for assessing the molecular and cellular mechanisms involved in therapeutic strategies for demyelinating diseases.
Authors
- Myriam Torres-Rico (ORCID: https://orcid.org/0000-0002-5222-2778)
- Carlos Luis Paı́no (ORCID: https://orcid.org/0000-0003-4245-592X)
- Jorge Pascual-Guerra (ORCID: https://orcid.org/0000-0001-6667-3310)
- Brenda Marin-Rodriguez
- Antonio G. Garcı́a (ORCID: https://orcid.org/0000-0002-6517-3565)
- J. A. Rodríguez-Navarro
- M. S. Arasmou-Idrovo
Institutions
- Universidad Complutense de Madrid (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Cells
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3390/cells14070533
- Citations
- 1
- Primary Topic
- Neurogenesis and neuroplasticity mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Agencia Laín Entralgo
- Instituto de Salud Carlos III
- European Regional Development Fund